Latest news with #ArtGarfunkel
Yahoo
4 days ago
- Entertainment
- Yahoo
MUSIC ICON ART GARFUNKEL GIVES HISTORIC CONCERT IN TEL AVIV PERFORMING WITH SON ART GARFUNKEL JR BEFORE AN AUDIENCE OF TENS OF THOUSANDS AMIDST ROCKET FIRE
Hi-res photo link found HERE. NEW YORK, May 30, 2025 /PRNewswire/ -- In a moment of profound cultural significance, music icon Art Garfunkel took the stage last night in Tel Aviv's Ha'Yarkon Park before a cheering crowd of over 50,000, becoming the first international artist to perform in Israel since the devastating attack at the Nova Music Festival in October 2023. Garfunkel was joined by his son, Art Garfunkel Jr. Prior to Garfunkel and Garfunkel taking the stage air raid sirens were heard due to missile fire reportedly targeting the concert in Tel Aviv. The father and son duo proceeded with their performance against a backdrop of missile interceptions. The emotional appearance of the family pair performing at Neshef Rock as Garfunkel & Garfunkel, soared on timeless classics including Bridge Over Troubled Water, The Sound of Silence, and Mrs. Robinson, weaving a musical thread between generations, resilience, and hope. The family duo's most recent album, Garfunkel & Garfunkel Father and Son, is available worldwide from BMG. Art Garfunkel Jr. was reported by Rolling Stone as one of Germany's most successful artists and continues to extend his own audience. "I am happy to be here in Israel," the 83-year-old performer told tens of thousands of cheering fans. "If Israel is in danger, the entire world is in danger," Garfunkel told the audience. "We all must not allow fear to define or control us. I am here with my entire family. Music is my gift from God, and my son Art Jr. is carrying our torch of music forward." Adding to the emotional weight of the evening, Garfunkel also performed The Boxer alongside Israeli rocker Aviv Geffen, uniting two eras of musical expression in a rare collaboration. Art was accompanied by his wife of many years, Kathryn "Kim" Luce Garfunkel—who is currently launching a new design and licensing initiative—and their younger son, Beau. The Garfunkel family's presence underscored the personal nature of this landmark event. Notably, Garfunkel has largely stepped back from public appearances and media in recent years making this live concert from Israel a rare and powerful moment. Media Contact:Victoria Varelavv@ View original content to download multimedia: SOURCE Carrberry Companies
Time of India
5 days ago
- Entertainment
- Time of India
Aviv Geffen's Concert Featuring Art Garfunkel Fails To Stop While Houthis Launch Missiles At Israel
Israeli Defense Forces (IDF) investigate the failure of security forces during a Tel Aviv concert as Houthis launched missiles. An Aviv Geffen concert, joined by American rock legend Art Garfunkel, reportedly continued despite the attack on Israel. A ballistic missile was launched by Yemen's Iran-backed Houthis late May 29, as per reports. This triggered air raid sirens across central Israel, but Israeli singer Geffen's concert continued. As per Times of Israel, IDF says it received reports that attendees did not hear siren during concert. At the same time, about tens of thousand had gathered at Bloomfield Stadium for Israeli soccer cup finals. The game was halted for 10 minutes before resuming, as reported by local media. Watch-
Yahoo
04-04-2025
- Entertainment
- Yahoo
Music Icon Art Garfunkel Opens Up About His Experience with Psoriasis for The First Time in Partnership with Sun Pharma
8X Grammy Award-winning artist and Rock and Roll Hall of Fame inductee reveals his experience with ILUMYA®(tildrakizumab-asmn) as part of the "I LUV YA for The Long Haul" campaign. PRINCETON, N.J., April 4, 2025 /PRNewswire/ -- Today, Sun Pharma announced its partnership with music icon and ILUMYA® (tildrakizumab-asmn) patient, Art Garfunkel, as he shares his story of living with moderate-to-severe plaque psoriasis in-depth for the first time publicly. Art, who was named one of Rolling Stone's "100 Greatest Singers of All Time," launched his career in the acclaimed duo "Simon & Garfunkel." Through the "I LUV YA for The Long Haul" campaign, Art joins a community of ILUMYA patients shedding light on the emotional toll of psoriasis and empowering others living with the condition to find the best treatment for them. While nearly 8 million Americans live with plaque psoriasis, its impact is often unseen or covered up.1 Art, whose music has touched millions worldwide, lived silently with his psoriasis—until now. "With support from my wife, Kim, and a treatment I trust, I am finally ready to give my history with psoriasis a voice," said Art. "After struggling for decades, I finally started ILUMYA about two years ago, and experiencing clearer skin has helped me regain my confidence. I am excited to share my story as part of the I LUV YA campaign in the hope that it will encourage others to find the right treatment for them." The "I LUV YA for The Long Haul," originally launched in May 2024, highlights the emotional impact psoriasis can have on a patient's life and how support – whether that be from a doctor, friend, or family member – can help navigate the challenges of managing their condition. The multi-part video series highlights real-life patient stories, including Art and how his wife, Kim, provided that support for him. "We are so honored to partner with Art Garfunkel to share his ILUMYA story and to bring greater awareness to the impact psoriasis has beyond the physical symptoms," said Maureen Shannon, Head of Biologics Marketing at Sun Pharma. "Art's music has impacted millions and his experience, shared for the first time, is sure to leave a lasting impression." To learn more about Art Garfunkel's experience and to learn more about ILUMYA as a treatment option, visit About Plaque Psoriasis Plaque psoriasis is a chronic, autoimmune disease that results in an overactive immune system and causes inflammation in the body, leading to symptoms like plaques, redness and flakes. It is estimated that nearly 8 million Americans live with plaque psoriasis.1 In plaque psoriasis, skin cells grow more rapidly than normal, rising to the surface of the skin in days rather than weeks. Life with plaque psoriasis can also be more than the physical symptoms – there can be an emotional impact as well. About ILUMYA (tildrakizumab-asmn) ILUMYA (tildrakizumab-asmn) is a humanized lgG1/k monoclonal antibody designed to selectively bind to the p19 subunit of interleukin-23 (IL-23) and inhibit its interaction with the IL-23 receptor, leading to inhibition of the release of pro-inflammatory cytokines and chemokines. ILUMYA is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, in the United States. ILUMYA has also been approved for moderate-to-severe plaque psoriasis in Australia and Japan, and under the brand name ILUMETRI® in Europe, where it is marketed by Almirall. INDICATIONS AND USAGE ILUMYA (tildrakizumab-asmn) is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. CONTRAINDICATIONSILUMYA is contraindicated in patients with a previous serious hypersensitivity reaction to tildrakizumab or to any of the excipients. IMPORTANT SAFETY INFORMATIONWARNINGS AND PRECAUTIONSHypersensitivityCases of angioedema and urticaria occurred in ILUMYA-treated subjects in clinical trials. If a serious allergic reaction occurs, discontinue ILUMYA immediately and initiate appropriate therapy. InfectionsILUMYA may increase the risk of infection. Treatment with ILUMYA should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated. Consider the risks and benefits of treatment prior to prescribing ILUMYA in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving ILUMYA to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and consider discontinuation of ILUMYA until the infection resolves. Pretreatment Evaluation for TuberculosisEvaluate patients for tuberculosis (TB) infection prior to initiating treatment with ILUMYA. Do not administer ILUMYA to patients with active TB infection. Initiate treatment of latent TB prior to administering ILUMYA. Consider anti-TB therapy prior to initiation of ILUMYA in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Patients receiving ILUMYA should be monitored closely for signs and symptoms of active TB during and after treatment. ImmunizationsPrior to initiating therapy with ILUMYA, consider completion of all age-appropriate immunizations according to current immunization guidelines. Patients treated with ILUMYA should not receive live vaccines. Adverse ReactionsThe most common (≥1%) adverse reactions associated with ILUMYA treatment that were more frequent than in the placebo group are upper respiratory infections, injection-site reactions, and diarrhea. Please see Full Prescribing Information. About Sun Pharmaceutical Industries LimitedSun Pharma is the world's leading specialty generics company with a presence in Specialty, Generics and Consumer Healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the U.S. as well as Global Emerging Markets. Sun's high-growth Global Specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. The company's vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents. Sun Pharma is proud of its multi-cultural workforce drawn from over 50 nations. For further information, please visit & follow us on LinkedIn & X (Formerly Twitter). DisclaimerStatements in this "Document" describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward-looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof. References View original content to download multimedia: SOURCE Sun Pharmaceutical Industries Inc., USA (Sun Pharma) Sign in to access your portfolio
